Search

US-12622920-B2 - Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion

US12622920B2US 12622920 B2US12622920 B2US 12622920B2US-12622920-B2

Abstract

A novel process of creating a cannabinoid pico-emulsion resulting in a sterile and injectable cannabinoid emulsion with increased bioavailability and antibiotic characteristics, and the resulting novel cannabinoid pico-emulsion, for the purpose of treating a wide variety of medical condition in both human and animals.

Inventors

  • Miles J. Terry
  • Robert Myers

Assignees

  • Miles J. Terry
  • Robert Myers

Dates

Publication Date
20260512
Application Date
20240615

Claims (16)

  1. 1 . A process for making sterile cannabinoid micelles in a pico-emulsion consisting essentially of: obtaining sterile cannabinoid micelles in a pico-emulsion which consist essentially of one or more cannabinoids covered by only one surfactant consisting of polysorbate 80, wherein the one or more cannabinoids are selected from the group consisting of purified Cannabichromene (CBC), purified Cannabinol (CBN), purified Cannabidiolic acid (CBDA), purified Cannabigerol (CBG), purified Cannabigerolic acid (CBGA), and combinations thereof, wherein the micelles are dispersed in water, and wherein the micelles are from about 850 picometers to about 4900 picometers.
  2. 2 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabichromene (CBC).
  3. 3 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabinol (CBN).
  4. 4 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabidiolic acid (CBDA).
  5. 5 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabigerol (CBG).
  6. 6 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabigerolic acid (CBGA).
  7. 7 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabidiolic acid (CBDA), purified Cannabigerol (CBG) and purified Cannabigerolic acid (CBGA).
  8. 8 . The process of claim 1 , wherein the one or more cannabinoids consist essentially of purified Cannabichromene (CBC), purified Cannabinol (CBN), purified Cannabidiolic acid (CBDA), purified Cannabigerol (CBG) and purified Cannabigerolic acid (CBGA).
  9. 9 . The process of claim 1 , wherein the one or more cannabinoids are at least 99% pure.
  10. 10 . The process of claim 1 , wherein obtaining the sterile cannabinoid micelles in a pico-emulsion consists essentially of heating the one or more cannabinoids and the surfactant, mixing with water to form a mixture, sonicating the mixture to produce micelles ranging in size from about 850 to about 4900 picometers, and filtering the micelles ranging in size from about 850 to about 4900 picometers.
  11. 11 . A process for making sterile cannabinoid micelles in a pico-emulsion consisting essentially of: obtaining sterile cannabinoid micelles in a pico-emulsion which consist essentially of cannabinoids covered by only one surfactant consisting of polysorbate 80, wherein the cannabinoids consist of purified Cannabichromene (CBC), purified Cannabidiol (CBD), purified Cannabinol (CBN), purified Cannabidiolic acid (CBDA), purified Cannabigerol (CBG), and purified Cannabigerolic acid (CBGA), wherein the micelles are dispersed in water, and wherein the micelles are from about 850 to about 4900 picometers.
  12. 12 . The process of claim 11 , wherein the cannabinoids are at least 99% pure.
  13. 13 . The process of claim 11 , wherein obtaining the sterile cannabinoid micelles in a pico-emulsion consists essentially of heating the cannabinoids and the surfactant, mixing with water to form a pre-sonicated mixture, sonicating the pre-sonicated mixture to produce micelles ranging in size from about 850 to about 4900 picometers, and filtering the micelles ranging in size from about 850 to about 4900 picometers.
  14. 14 . A process for making sterile cannabinoid micelles in a pico-emulsion consisting essentially of: obtaining sterile cannabinoid micelles in a pico-emulsion which consist essentially of cannabinoids covered by only one surfactant consisting of polysorbate 80, wherein the cannabinoids consist of purified Cannabidiol (CBD), purified Cannabidiolic acid (CBDA), purified Cannabigerol (CBG), and purified Cannabigerolic acid (CBGA), wherein the micelles are dispersed in water, and wherein the micelles are from about 850 to about 4900 picometers.
  15. 15 . The process of claim 14 , wherein the cannabinoids are at least 99% pure.
  16. 16 . The process of claim 14 , wherein obtaining the sterile cannabinoid micelles in a pico-emulsion consists essentially of heating the cannabinoids and the surfactant, mixing with water to form a mixture, sonicating the mixture to produce micelles ranging in size from about 850 to about 4900 picometers, and filtering the micelles ranging in size from about 850 to about 4900 picometers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This United States Non-Provisional Utility Patent Applications claims the priority date of U.S. Provisional Application No. 63/521,641, titled: “CANNABINOID PICO EMULSION,” filed Jun. 16, 2023 in the United States Patent and Trademark Office, the disclosure of which is hereby incorporated by reference in its entirety. FIELD OF THE PRESENT DISCLOSURE This disclosure relates generally to medical grade cannabinoid-based products, and more specifically to a process of creating a sterile and injectable cannabinoid pico-emulsion featuring increased bioavailability and antibiotic characteristics, and the resulting novel cannabinoid pico-emulsion. BACKGROUND As our understanding of the medicinal properties of cannabis continues to evolve, there has been a notable surge in the exploration and utilization of THC (tetrahydrocannabinol), CBD (cannabidiol), and other cannabis-derived compounds for various medical purposes, and with an expanding body of research providing scientific evidentiary support, cannabis-derived compounds are increasingly being integrated into mainstream medical protocols for treating a wide range of medical conditions. Traditionally, the method of consumption or route of administration of cannabis has been limited to either smoking or ingesting edibles. While these legacy modes of administration offer certain benefits, they also come with notable drawbacks and limitations. For example, smoking cannabis involves the inhalation of smoke, which can irritate the respiratory system and includes other harmful byproducts of combustion that may pose risks to overall health over time. Further, some individuals may disfavor smoking as a route of administration because it necessarily exposes others in the immediate area to second hand smoke. Some of these concerns can be mitigated by the use of e-cigarettes or vaping; however, vaping is associated with various health risks as well. Smoking and vaping may also be disfavored by some individuals seeking to treat medical conditions with cannabis because such legacy delivery systems are traditionally associated with recreational cannabis use which may still be associated with stigmas and other various social sentiments, both positive and negative. The introduction of cannabis-based compounds through the consumption edibles can be much more discreet than smoking or vaping but this route of administration is associated with its own limitations as well. For example, edibles are traditionally associated with delayed onset of effects and unpredictable potency, making it challenging to control dosage and very difficult to achieve immediate effects. One reason for the challenges related to predicting potency when ingesting cannabis-based compounds is that the digestive tract metabolizes THC, CBD, and other cannabinoids before they can reach the bloodstream. This process, known as first-pass metabolism, reduces the amount of the desired cannabinoid that ultimately enters the bloodstream, leading to decreased bioavailability and potentially requiring higher initial doses to achieve the desired effects. Additionally, when THC is metabolized, it can produce metabolites such as 11-hydroxy-THC (also known as Delta-11) and Delta-10-THC, which may remain in the body for longer periods than THC itself. This prolonged presence of metabolites can increase the risk of failing a drug test even when the psychoactive effects of the THC, or other desired effects of the target cannabinoid, have subsided presenting an unnecessary concern for individuals using cannabis for medical purposes. Recognizing the limitations of legacy delivery methods, there is a growing interest in alternative routes of administration that offer enhanced dosing precision, immediate bioavailability, and therapeutic efficacy. One such approach is the development of injectable or intravenous formulations of cannabis-derived compounds. By administering cannabinoids directly into the bloodstream, injectable formulations bypass the digestive system and liver metabolism, leading to faster onset of action and increased bioavailability compared to legacy modalities. Moreover, injectable cannabis formulations offer the potential for more precise dosing, allowing healthcare providers to more precisely tailor treatment regimens to individual patients' needs. This can be particularly beneficial for conditions requiring rapid symptom relief or for patients with lung or gastrointestinal issues that may impair or limit absorption into the bloodstream by legacy routes of administration. One important parameter when developing an injectable or intravenous cannabis formulations is emulsion droplet or micelle size. Generally speaking, the smaller the droplet size, the greater the bioavailability. Some researchers have also attempted to achieve greater cannabinoid bioavailability by altering the polarity of the cannabinoid molecule to increase its solubility through glycosylation. Glycosyla